By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today announced it has received approval from the US Food and Drug Administration to market the Abbott RealTime HBV assay for measuring the viral load of hepatitis B in patients.

The test is the first automated molecular test for assessing HBV viral load to receive FDA approval, Abbott said.

Other molecular HBV tests that aren't automated that have received FDA approval include Roche's Cobas TaqMan HBV Test and Gen-Probe's Procleix Ultrio assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.